| Ytd | -41.71% | |
| 1y | -40.43% |
| Open | 5.36 | Prev Close | 5.44 | Low | 5.36 | High | 5.36 | Mkt Cap | 33.66M |
| Vol | 669.00 | Avg Vol | 177.95K | EPS | -8.69 | P/E | -0.63 | Forward P/E | -3.30 |
| Beta | 2.26 | Short Ratio | 0.50 | Inst. Own | 48.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.68 | 200-d Avg | 7.61 | 1yr Est | 103.33 |
ALGS News
Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical compa
SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL
Aligos Therapeutics stock rose in after-hours trading after a $25 million licensing payment and Chin
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-m
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on impro
Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Cali
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 r
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Ph
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduc
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALG
Akamai Technologies Inc (NASDAQ: AKAM) rose in pre-market trading after reporting strong Q1 results
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALG
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A
SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A
Aligos Therapeutics, Inc. (NASDAQ: ALGS - Get Free Report) has been assigned a consensus rating of "
The agreement aims to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus (
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for it
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
During Thursday, 849 stocks hit new 52-week lows.
On Thursday, 147 companies achieved new lows for the year.
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e